Want to see AU:EXL full AI Analyst Report?
Top Page
Elixinol Wellness
(Sydney:EXL)
Select Model
Select Model
Rating:50Neutral
Price Target:
AU$0.02
▼(-25.00% Downside)
Action:Reiterated
Date:05/16/26
The score is held back primarily by weak profitability and valuation, while improving revenue trends, cost cuts, and constructive short-term technicals provide some offset. The lack of positive earnings and dividend support remains the biggest constraint.
Positive Factors
Higher‑margin D2C / e‑commerce mix
A sustained shift to higher‑margin direct‑to‑consumer sales improves gross margins and cash predictability long term. Digital sales growth (and repeat D2C relationships) reduces dependence on low‑margin wholesale and gives scalable customer economics if acquisition and retention stay efficient.
Negative Factors
Persistent negative operating cash flow
Ongoing negative OCF and FCF mean the business cannot self‑fund growth or working capital and will remain reliant on external financing. Persistent cash burn limits flexibility, raises refinancing risk if markets tighten, and constrains investment in marketing, R&D, or distribution needed to scale revenues.
Read all positive and negative factors
Positive Factors
Negative Factors
Higher‑margin D2C / e‑commerce mix
A sustained shift to higher‑margin direct‑to‑consumer sales improves gross margins and cash predictability long term. Digital sales growth (and repeat D2C relationships) reduces dependence on low‑margin wholesale and gives scalable customer economics if acquisition and retention stay efficient.
Read all positive factors
Elixinol Wellness (EXL) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$2.69M
Dividend YieldN/A
Average Volume (3M)554.74K
Price to Earnings (P/E)―
Beta (1Y)-0.84
Revenue Growth3.64%
EPS Growth-23.56%
CountryAU
Employees15
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.02
Shares Outstanding413,987,730
10 Day Avg. Volume558,811
30 Day Avg. Volume554,744
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.31
Price to Sales (P/S)0.15
P/FCF Ratio-0.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Elixinol Wellness Business Overview & Revenue Model
Company Description
Elixinol Wellness Limited, an entity established in 2017 and headquartered in Sydney, Australia, operates internationally through its subsidiaries. The company is primarily involved in the manufacturing and global distribution of a wide array of h...
How the Company Makes Money
Elixinol Wellness makes money primarily by selling branded hemp/CBD wellness products to consumers and trade customers. Its core revenue streams are (1) direct-to-consumer sales via company-controlled e-commerce channels, where the company capture...
Elixinol Wellness Earnings Call Summary
Earnings Call Date:Feb 12, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Aug 27, 2026
Earnings Call Sentiment Positive
The call communicated meaningful operational progress: a clear shift to higher-margin channels (e-commerce up to 38%), significant cost structure reduction (~30% in Q4 vs prior year), Q4 profitability and positive operating cash flow, strong D2C momentum (Healthy Chef e-commerce +42% YoY) and product innovation poised to capture market trends. However, challenges remain including modest full-year revenue growth (3.6% YoY), a small absolute revenue base (~$15.5M), supermarket channel pressures for niche SKUs, and regulatory uncertainty in the U.S. CBD business. On balance, the operational improvements and trajectory toward sustainable profitability outweigh the outstanding strategic and market risks, but execution and regulatory clarity will be important near-term drivers.Positive Updates
Q4 Revenue Growth and Strong Exit Run-Rate
Q4 FY25 revenue of $4.1M, up 9.5% quarter-on-quarter, delivering a strong exit run-rate into FY26 and demonstrating seasonal rebound in the business.
Negative Updates
Modest Full-Year Top-Line Growth
FY25 revenue growth was modest at 3.6% year-over-year ($15.5M), indicating limited top-line expansion despite improvements in mix and margins.
Read all updates
Q4-2025 Updates
Positive
Negative
Q4 Revenue Growth and Strong Exit Run-Rate
Q4 FY25 revenue of $4.1M, up 9.5% quarter-on-quarter, delivering a strong exit run-rate into FY26 and demonstrating seasonal rebound in the business.
Read all positive updates
Company Guidance
Management guided FY26 around four pillars — operational momentum, cost efficiency, building a growth foundation and targeted M&A — with the aim of maintaining a structurally lower OpEx run‑rate after cutting the operating cost base by ~30% in Q4 vs Q4 FY24 and delivering Q4 positive EBITDA (slightly better than break‑even) and positive underlying operating cash flow; they completed a two‑tranche $2.5m capital raise and will review capital management at the May AGM. The company will prioritize higher‑margin D2C and e‑commerce (e‑commerce grew from 21% to 38% of revenue in 2025; Healthy Chef e‑commerce +42% YoY in Q4) while reducing low‑margin bulk (from 24% to 14%), leveraging FY25 revenue of $15.5m and a Q4 exit run‑rate of $4.1m (quarterly revenue ranged ~$3–4m) with contracted hemp volumes up for 2026. Management also signalled near‑term actions — pursuing value‑accretive acquisitions, keeping U.S. CBD options open pending regulatory clarity in 2–3 months, and driving product launches (Healthy Chef Metabolic Burn and protein water, plus Mt Elephant NPD into Coles in May) to capture large market opportunities (Australia wellness ~$160bn today to >$300bn by 2033 at ~7% growth, functional foods ~$10.5bn, protein market to $1.1bn by 2034) and narrow the current valuation gap (~0.3x revenue vs peers 1–1.5x).Elixinol Wellness Financial Statement Overview
Summary
Income Statement
25
Negative
Balance Sheet
65
Positive
Cash Flow
30
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 15.50M | 14.96M | 8.27M | 7.05M | 9.34M |
| Gross Profit | 752.00K | 5.36M | -1.80M | -3.27M | -6.25M |
| EBITDA | -4.11M | -4.01M | -6.81M | -9.28M | -15.51M |
| Net Income | -5.50M | -1.72M | -7.51M | -10.57M | -17.02M |
Balance Sheet | |||||
| Total Assets | 15.96M | 18.45M | 11.71M | 13.48M | 25.33M |
| Cash, Cash Equivalents and Short-Term Investments | 1.41M | 1.08M | 708.00K | 2.86M | 12.65M |
| Total Debt | 3.73M | 1.94M | 1.26M | 1.83M | 2.71M |
| Total Liabilities | 8.51M | 8.42M | 5.25M | 4.33M | 6.25M |
| Stockholders Equity | 7.45M | 10.03M | 6.46M | 9.16M | 19.08M |
Cash Flow | |||||
| Free Cash Flow | -3.28M | -3.53M | -2.77M | -8.16M | -14.36M |
| Operating Cash Flow | -3.21M | -3.47M | -2.76M | -8.15M | -14.07M |
| Investing Cash Flow | -216.00K | -66.00K | -1.04M | -869.00K | 172.00K |
| Financing Cash Flow | 3.65M | 3.92M | 1.61M | -757.00K | -1.16M |
Elixinol Wellness Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | AU$135.38M | 13.39 | 19.15% | 4.33% | 17.31% | 17.99% | |
53 Neutral | AU$60.44M | -16.30 | -1.67% | ― | 15.21% | -141.82% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$15.91M | 20.00 | 1.66% | 6.67% | 2.11% | -64.71% | |
50 Neutral | AU$2.69M | -0.28 | -76.30% | ― | 3.64% | -23.56% | |
48 Neutral | AU$5.81M | 0.35 | 93.89% | ― | -29.95% | ― | |
39 Underperform | AU$21.35M | -5.07 | 4388.00% | ― | -53.90% | 57.52% |
* Healthcare Sector Average
AU:EXL
Elixinol Wellness
0.02
>-0.01
-11.76%
AU:CAN
Cann Group
0.01
>-0.01
-28.57%
AU:VLS
Vita Life Sciences Limited
2.45
0.41
19.92%
AU:LGP
Little Green Pharma Ltd.
0.07
-0.04
-34.55%
AU:PKP
Althea Group Holdings Ltd.
0.02
>-0.01
-28.57%
AU:VIT
Cronos Australia Ltd.
0.02
-0.04
-64.18%
Elixinol Wellness Corporate Events
Elixinol streamlines register with small parcel share sale
Jun 18, 2026
Elixinol Wellness has completed a small parcel share sale facility, disposing of minimum holdings valued at less than A$500 on behalf of 7,387 shareholders and generating total proceeds of A$112,731.21 at an average price of A$0.006 per share. Par...
Elixinol Wellness Wins Strong Shareholder Backing for Capital-Raising Flexibility
May 27, 2026
Elixinol Wellness shareholders overwhelmingly backed all resolutions at the company’s 27 May annual general meeting, including the adoption of the remuneration report and the election and re-election of directors Gavin Evans and Pauline Gate...
Elixinol Wellness Issues Risk-Focused Disclaimer With FY25 AGM Materials
May 26, 2026
Elixinol Wellness has released materials for its FY25 Annual General Meeting, emphasising that the information is for general purposes only and should not be the sole basis for investment decisions. The company underscores that its securities carr...
Elixinol Wellness signals turnaround as focus shifts to higher-margin everyday wellness platform
May 26, 2026
Elixinol Wellness used its latest annual general meeting to highlight a successful turnaround over FY25, shifting from survival to stability as it tightened financial discipline, cut costs and sharpened its strategic focus. The group now presents ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.